Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of LY900014 vs Humalog in T2DM
NCT03305822Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of insulin lispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours. Started Oct 2017; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03305822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305822.